Healius stock falls 1.37 percent as Agilex sale reshapes group
Published on 09/24/2026 at 21:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Healius stock (ASX:HLS) fell 1.37 percent to AUD 0.36 on the ASX on September 23, 2026, valuing the healthcare group at AUD 261.4 million. The company has also sold Agilex Biolabs to Novotech, a transaction that narrows the portfolio toward its core pathology operations, as Australian Financial Review reported on September 24, 2026.
Agilex sale changes the mix
The divestment matters because Agilex was the group's faster-growing business. In FY2026, Agilex revenue increased 14.1 percent to AUD 43.6 million, while Agilex EBITDA rose AUD 4.3 million to AUD 10.7 million, according to Yahoo Finance in its FY2026 earnings-call transcript.
That growth now leaves the group through a sale process that places greater weight on pathology earnings, cost control and fee mix. Healius operates one of Australia's largest pathology networks, with one in every three pathology samples processed in its laboratories, according to the company's investor page.
Revenue grows while margins stay thin
Healius generated underlying revenue of AUD 1.37 billion in FY2026, up 2.1 percent from the previous year. Underlying EBITDA increased 8.1 percent to AUD 258.6 million, while underlying EBIT rose to AUD 30.2 million from AUD 17.1 million, the earnings-call transcript said.
The comparison shows the central tension in the stock. Earnings improved faster than revenue, but the absolute EBIT base remains modest against group sales, leaving operating leverage and pathology volumes as key measures for the next reporting cycle.
Stock trades near yearly low
Healius stock stood at AUD 0.36 on the ASX on September 23, 2026, against a 52-week range of AUD 0.30 to AUD 1.07. The share price was therefore AUD 0.06 above its yearly low and AUD 0.71 below its yearly high.
The current market value and the FY2026 operating figures point to a company in transition: the Agilex disposal simplifies the portfolio, while pathology must convert revenue growth into a wider EBIT margin.
Healius Limited at a glance
- Company: Healius Limited
- Ticker: HLS
- Trading venue: ASX
- Price as of September 23, 2026: AUD 0.36
- Market capitalization: AUD 261.4 million as of September 23, 2026
- 52-week range: AUD 0.30-1.07 as of September 23, 2026
- Sector / Industry: Health Care / Healthcare Facilities and Services
- Index membership: S&P/ASX Emerging Companies Index
